Secukinumab

[MAF] Secukinumab (Cosentyx) Injection, Prefilled Pen 150 mg/mL

1. Additional clinical criteria applies

2. Treatment of adult patients with ankylosing spondylitis

3. Treatment of adult patients with psoriatic arthritis with axial involvement

4. Treatment of adult patients with psoriatic arthritis with peripheral involvement

5. Treatment of adult patients with chronic plaque psoriasis

6. Treatment of children and adolescents aged 6 years and above with chronic plaque psoriasis

7. Treatment of adult patients with non-radiographic axial spondyloarthritis (axSpA).

[MAF] Secukinumab (Cosentyx) Injection, Prefilled Pen 300 mg/2 mL

1. Additional clinical criteria applies

2. Treatment of adult patients with ankylosing spondylitis

3. Treatment of adult patients with psoriatic arthritis with axial involvement

4. Treatment of adult patients with psoriatic arthritis with peripheral involvement

5. Treatment of adult patients with chronic plaque psoriasis

6. Treatment of children and adolescents aged 6 years and above with chronic plaque psoriasis

[MAF] Secukinumab (Cosentyx) Prefilled Syringe 75 mg/0.5 mL

1. Additional clinical criteria applies
   
   Treatment of children and adolescents aged 6 years and above with chronic plaque psoriasis

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

01/06/2023 Ixekizumab and secukinumab for treating active non-radiographic axial spondyloarthritis

The Ministry of Health’s Drug Advisory Committee has recommended:

• Secukinumab 150 mg/mL solution for injection in prefilled pen for treating adults with active non-radiographic axial spondyloarthritis.

Funding status

[R] Secukinumab 150 mg/mL solution for injection in prefilled pen is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2023.

[R] Secukinumab should be used in line with additional clinical criteria for initial and continuing prescriptions for adult patients with active non-radiographic axial spondyloarthritis.

[NR] MAF assistance does not apply to ixekizumab, or any other formulations or strengths of secukinumab.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration